HoFH, the International Clinical Collaborators Registry

Study Overview
=================
Brief Summary
-----------------
Homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder caused by bi-allelic mutations in the LDL Receptor pathway, is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth and premature atherosclerotic cardiovascular disease (ASCVD). Our current knowledge about HoFH is disjointed and largely stems from relatively small case series and expert opinion. HICC (Homozygous FH International Clinical Collaborators) is a global consortium of clinicians who are contributing de-identified data of patients diagnosed with HoFH with the goal to advance our understanding of this rare disease.

Detailed Description
-----------------
The HICC registry is an observational, multicenter, international registry collecting de-identified clinical and genetic information from patients with homozygous Familial Hypercholesterolemia (HoFH) worldwide. Patients are eligible to be enrolled in the registry based on the diagnosis of HoFH by the treating clinician, irrespective of how the diagnosis was made. To generate up-to-date data reflecting current rather than historic practice, patients who died or were lost to follow-up prior to 2010 are excluded. Anonymized data on demographics, type of HoFH diagnosis (clinical and/or based on the results of a genetic test), genetic results, (cardiovascular) medical history, relevant family history, physical examination, laboratory measurements, lipid lowering treatment and cardiovascular imaging are collected for 3 different time points: at diagnosis, at enrolment and at time of best lipid profile (if this is different from time at enrolment). Data are collected using pre-definite electronic case report forms to ensure uniformity of data collected. Primary analysis will be cross-sectional (e.g. based on country of residence, age, etc)

Official Title
-----------------
HoFH, the International Clinical Collaborators - A Global HoFH Data-sharing Platform

Conditions
-----------------
Homozygous Familial Hypercholesterolemia

Intervention / Treatment
-----------------
* Other: Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of homozygous familial hypercholesterolemia (HoFH) clinically of genetically determined Exclusion Criteria: No diagnosis of HoFH
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HoFH<br>Patients diagnosed with HoFH by their physicians, either based on clinical or genetic criteria. | Other: Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.<br>* Differences in diagnosis, genotype, lipid profile treatment allocation among HoFH patients worldwide.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants entered into the database | Number of study participants with homozygous familial hypercholesterolemia | Through study completion, an average of 8 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Untreated and treated LDL-C levels across world income regions | Number of treated versus number of untreated subjects with relevant LDL-C levels | Through study completion, an average of 8 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Homozygous Familial Hypercholesterolemia, Autosomal Dominant, Hypercholesterolemia, Autosomal Recessive Hypercholesterolemia, Registry